New therapeutic option for mantle cell lymphoma, AIFA approves Pirtobrutinib

2024-10-23 16:13:00

The Italian Medicines Agency (AIFA) recently approved the reimbursement of pirtobrutinib, a new drug for the treatment of relapsed or refractory mantle cell lymphoma. This type of blood cancer, which affects around 860 people every year in Italy, originates from B lymphocytes and often occurs in the lymph nodes. Pirtobrutinib, prescribed by hematologists and taken orally, represents a breakthrough in the treatment of patients who have already received an inhibitor, but who have seen the disease return.